Epizyme Soars On Blood-Cancer Drug Data
Lagging biotech stock Epizyme (EPZM) suddenly came to life Monday, jumping more than 30% in the wake of positive weekend data on its lymphoma drug. On Saturday at the annual International Conference on Malignant Lymphoma, Epizyme said that nine out of 15 advanced non-Hodgkins lymphoma (NHL) patients in a phase one study responded to tazemetostat (EPZ-6438), a first-in-class drug called an EZH2 inhbitor. Five of nine patients with diffuse large